What is Stevanato Group's latest dividend and current dividend yield?

What factors drove the changes in Stevanato Group's revenue and profit?

What were the key takeaways from Stevanato Group’s earnings call?

What does Stevanato Group do and what are its main business segments?

What is the revenue and EPS growth rate for Stevanato Group year over year?

What is Stevanato Group's gross profit margin?

Did Stevanato Group beat or miss consensus estimates last quarter?

What were the key takeaways from Stevanato Group's earnings call?

- **Revenue Beat Expectations**: Q3 2025 revenue of $303.2 million (+9% YoY) exceeded guidance, driven by a 14% surge in the BDS segment.
- **High-Value Solutions Surge**: 47% growth in high-value solutions (49% of total revenue) highlights strong demand for Nexa syringes and EZ-fill cartridges.
- **Margin Expansion**: Gross profit margin improved 240 bps to 29.2%, with adjusted EBITDA margin up 220 bps to 25.7%.
- **Strategic Investments Paying Off**: Fisher and Latina plants progressing toward full capacity, with commercial activities set to begin late 2026/early 2027.
- **Biosimilar Growth Driver**: Secured biosimilar business (e.g., GLP-1) underscores long-term growth in high-value solutions.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue rose 9% YoY to $303.2 million, driven by a 14% increase in the BDS segment, offsetting a 19% decline in the Engineering segment.
- **High-Value Solutions Dominance**: High-value solutions grew 47% to $117.9 million, accounting for 49% of total revenue, with Nexa syringes and EZ-fill cartridges leading demand.
- **Engineering Segment Challenges**: The Engineering segment faced a 19% revenue decline due to lower glass conversion and assembly line revenue, though site acceptance tests (SATs) improved.
- **Capital Projects Progress**: Fisher and Latina plants are ramping up production, with commercial activities expected to begin in late 2026/early 2027. EcoVadis silver medal awarded for ESG performance.

**【CFO Financial Commentary】**
- **Gross Profit Margin Expansion**: Consolidated gross profit margin increased 240 bps to 29.2%, driven by high-value solutions and operational improvements at Fisher and Latina.
- **Adjusted EBITDA**: $77.8 million, with a 220 bps improvement in adjusted EBITDA margin to 25.7%.
- **Guidance Update**: Reiterated 2025 guidance with high-value solutions expected to account for 43-44% of revenue (up from 40-42%), and currency impact now $15-16 million (vs. $12-15 million).
- **Free Cash Flow**: Positive free cash flow of $260,000 in Q3 and $16.9 million year-to-date.

**【Q&A Highlights】**
- **Revenue Pull Forward**: $10 million of Q4 revenue was accelerated into Q3 due to customer supply chain needs, primarily in high-value syringes.
- **Plant Margins**: Fisher plant not yet profitable but improving; Latina plant nearing normalized margins.
- **Engineering Segment Recovery**: Slow order conversion due to customers awaiting SATs and reevaluating manufacturing footprints; cautious optimism for 2026 recovery.
- **Biosimilar Growth**: Winning biosimilar business (e.g., GLP-1) driving demand for high-value solutions like Nexa syringes and EZ-fill cartridges.
- **U.S. Manufacturing Trends**: Customers onshoring production in the U.S. to meet Annex 1 regulations, creating opportunities for Fisher plant utilization.


Stevanato Group S.p.A. (STVN) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

STVN

STVN fundamentals

You can ask Aime